secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001493152-25-004948
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer
--------------------------------------------------------------------------------

- Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.
- Phase 2 enrollment expected to commence imminently; up to 25 patients to be enrolled.
- Combination therapy uses AIM's Ampligen and AstraZeneca's Imfinzi for late-stage pancreatic cancer.
- Phase 1 data showed combination generally well-tolerated; some patients had stable disease for 15+ months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315225004948/0001493152-25-004948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315225004948/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-004948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer